Y Intercept Hong Kong Ltd Sells 140,619 Shares of Verastem, Inc. $VSTM

Y Intercept Hong Kong Ltd trimmed its stake in Verastem, Inc. (NASDAQ:VSTM) by 90.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,298 shares of the biopharmaceutical company’s stock after selling 140,619 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Verastem were worth $126,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. E Fund Management Co. Ltd. purchased a new position in shares of Verastem in the 2nd quarter worth about $49,000. Nebula Research & Development LLC purchased a new stake in Verastem during the 2nd quarter valued at about $53,000. The Manufacturers Life Insurance Company increased its stake in Verastem by 9.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 1,440 shares in the last quarter. Profund Advisors LLC purchased a new position in Verastem in the second quarter worth about $90,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Verastem in the second quarter worth approximately $106,000. 88.37% of the stock is owned by hedge funds and other institutional investors.

Verastem Price Performance

NASDAQ VSTM opened at $6.67 on Friday. The company has a 50-day moving average price of $7.75 and a 200-day moving average price of $8.26. Verastem, Inc. has a 52 week low of $4.01 and a 52 week high of $11.24. The company has a quick ratio of 2.55, a current ratio of 2.58 and a debt-to-equity ratio of 2.06. The firm has a market capitalization of $445.42 million, a P/E ratio of -1.66 and a beta of 0.41.

Verastem (NASDAQ:VSTM) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.84). The company had revenue of $11.24 million for the quarter, compared to the consensus estimate of $5.76 million. Equities research analysts anticipate that Verastem, Inc. will post -3.02 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Daniel Calkins sold 5,039 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $7.16, for a total value of $36,079.24. Following the transaction, the chief financial officer owned 104,719 shares of the company’s stock, valued at $749,788.04. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Kauffman sold 8,550 shares of Verastem stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $10.00, for a total value of $85,500.00. Following the transaction, the director directly owned 8,666 shares in the company, valued at approximately $86,660. The trade was a 49.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 50,478 shares of company stock valued at $462,045 over the last three months. 2.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on VSTM. HC Wainwright assumed coverage on shares of Verastem in a research report on Wednesday. They set a “buy” rating and a $18.00 price target for the company. Guggenheim reissued a “buy” rating on shares of Verastem in a report on Tuesday, December 30th. Zacks Research downgraded Verastem from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Wall Street Zen cut Verastem from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Cantor Fitzgerald raised Verastem to a “strong-buy” rating in a research report on Thursday, October 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.83.

More Verastem News

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 revenue came in stronger than investors expected, driven by sales from the Avmapki Fakzynja co‑pack partnership; the release prompted the near‑term stock rally. Verastem preliminary results
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and an $18 price target and updated long‑range EPS forecasts — notably raising FY2028 and FY2029 estimates and projecting much larger positive EPS by FY2030 — signaling growing analyst confidence in Verastem’s path to profitability. This analyst support likely amplified buying interest. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: CEO Dan Paterson filed a small sale of 970 shares at about $6.69 on Feb. 4; the sale is modest relative to his remaining holdings and likely has limited informational weight for investors. SEC filing
• Negative Sentiment: HC Wainwright’s near‑term forecasts still show multi‑year losses (FY2025–FY2027 and FY2026 EPS pegged negative), so while long‑term outlook is improving, the company remains unprofitable in the medium term — a risk for investors focused on near‑term cash burn or dilution. HC Wainwright estimates (MarketBeat)

Verastem Company Profile

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.